Publicity sees the light of a new French study, according to which the risk of potentially life-threatening venous thromboembolism is increased and in patients with moderate Covid-19, who are not seriously ill, something that so far has been associated mainly with patients with severe Covid-19.
More specifically, the researchers, who made the relevant publication in the journal “Thrombosis Research”, according to Reuters, studied 2,292 patients with mild to moderate Covid-19. After four weeks, it was found that venous thromboembolism had occurred approximately one in 200 (0.6%) mildly ill patients who did not need hospitalization but remained at home as well five in 200 (2.3%) with moderate disease, who had been hospitalized. Overall, the risk of venous thromboembolism was on average 1.7% higher in Covid-19 patients compared with those without coronavirus infection.
The study highlights the need for physicians caring for patients with mild to moderate Covid-19 to be aware of the risk of developing venous thromboembolism, especially if a patient is over 65 years and eventually need hospitalization, even though he is not seriously ill.
Coronavirus: Treatment for thrombosis
According to the APE-MPE, a second study, published in the American medical journal “JAMA Internal Medicine”, led by the Greek-American professor of medicine Alex Spyropoulos of the Feinstein Institute for Medical Research in New York, found that in patients -19, who are considered to be at high risk for dangerous blood clots, anticoagulant therapy with high doses of low molecular weight heparin (HCMB) significantly reduces the chance of blood clot formation and death.
Randomized clinical trial in 253 adult patients with a mean age of 67 years showed 32% reduction in the risk of death if a high dose of this heparin was administered, relative to the usual dose. As Dr. Spyropoulos said, “the clinical trial was done because we saw patients show blood clots and die in front of us while taking standard doses of heparin as a precaution.”
The probability severe bleeding was slightly higher (4.7%) in patients taking high-dose anticoagulants than usual (1.6%). High-dose efficacy was present in non-ICU patients, but not in ICU patients.
Here and here you will see the relevant scientific publications.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
